Alx Oncology Holdings Inc Stock Price, News & Analysis

ALX Oncology Holdings Inc. (Nasdaq: ALXO) announced participation in two upcoming virtual investor conferences. CEO Jaume Pons and senior executives will engage in fireside chats at the 29th Annual Credit Suisse Virtual Healthcare Conference on November 9 and the Jefferies Virtual London Healthcare Conference on November 19. ALX Oncology is focused on developing therapies that inhibit the CD47 checkpoint pathway, with its lead product candidate, ALX148, showing promising clinical results against various cancers. Webcast links are provided for interested investors.

ALX Oncology (Nasdaq: ALXO) has initiated the Phase 1/2 ASPEN-02 study to evaluate the safety and efficacy of ALX148 combined with azacitidine for treating higher-risk myelodysplastic syndrome (MDS). The first patient has been dosed in this clinical trial, which is based on promising preclinical and clinical data. The trial aims to assess the safety of this combination in patients with previously untreated or relapsed MDS. If successful, the Phase 2 component will follow, focusing on efficacy. ALX148 has previously shown potential in multiple malignancies.

ALX Oncology Holdings Inc. (Nasdaq: ALXO) has established a Scientific Advisory Board (SAB) featuring three renowned oncology experts to provide strategic guidance for its clinical programs, particularly for its lead candidate, ALX148. This next-generation therapy targets the CD47 checkpoint pathway, aiming to minimize hematologic toxicity seen in existing treatments. The SAB members include Keith Flaherty, M.D., Charles Baum, M.D., Ph.D., and Kipp Weiskopf, M.D., Ph.D., who collectively bring extensive expertise in oncology and drug development.

ALX Oncology (NASDAQ: ALXO) has announced a clinical trial collaboration with Merck to evaluate ALX148, a CD47 blocker, combined with KEYTRUDA for treating Head & Neck Squamous Cell Carcinoma (HNSCC). This Phase 2 program includes two studies: one assessing the efficacy of ALX148 and KEYTRUDA, and the second adding standard chemotherapy. The collaboration follows promising Phase 1b trial data showing a 40% objective response rate in patients treated with ALX148 and KEYTRUDA. ALX148 is positioned as a key immunotherapy in cancer treatment.

ALX Oncology Holdings Inc. (Nasdaq: ALXO) announced its inclusion in the Russell 2000® and 3000® Indexes effective September 18, 2020, two months post-IPO. This inclusion is a significant milestone, enhancing visibility and awareness among investors.

The Russell Indexes are crucial benchmarks for approximately $9 trillion in assets, widely utilized by institutions for index funds and investment strategies. ALX Oncology is focused on developing therapies to block the CD47 checkpoint pathway, with its lead candidate, ALX148, showing promising clinical responses.

BURLINGAME, Calif., Sept. 08, 2020 – ALX Oncology Holdings (Nasdaq: ALXO) announced participation in two virtual investor conferences in September. The Cantor Virtual Healthcare Conference will feature a fireside chat on September 15 at 1:20 PM ET. The H.C. Wainwright 22nd Annual Global Investment Conference will be held on September 16 at 2:30 PM ET. Management will also engage in one-on-one meetings at both events. Live webcasts can be accessed via ALX Oncology’s website, and replays will be available for 90 days.

ALX Oncology Holdings Inc. (Nasdaq: ALXO) announced significant operational and financial updates on August 27, 2020. The company raised $185.7 million through its initial public offering completed on July 21, 2020. ALX148, their lead candidate, has received FDA clearance to proceed with clinical trials in combination with azacitidine for higher-risk myelodysplastic syndromes. Financial results for Q2 show a net loss of $14.0 million, with cash equivalents at $98.1 million, expected to fund operations through 2023. R&D expenses increased significantly, reflecting heightened clinical development efforts.

ALX Oncology Holdings Inc. (Nasdaq: ALXO) has successfully closed its IPO of 9,775,000 shares of common stock at a price of $19.00 per share, generating approximately $185.7 million in gross proceeds. This includes the full exercise of underwriters' options for an additional 1,275,000 shares. The shares began trading on the Nasdaq Global Select Market on July 17, 2020. The offering was managed by Jefferies, Credit Suisse, Piper Sandler, and Cantor Fitzgerald.